Arizona State Retirement System Lowers Stake in Integer Holdings Co. (NYSE:ITGR)

Arizona State Retirement System reduced its position in shares of Integer Holdings Co. (NYSE:ITGR) by 1.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,311 shares of the medical equipment provider’s stock after selling 163 shares during the quarter. Arizona State Retirement System’s holdings in Integer were worth $923,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Trust Point Inc. purchased a new stake in shares of Integer during the 4th quarter worth about $874,000. LVZ Inc. purchased a new stake in shares of Integer during the 4th quarter worth about $239,000. Blue Trust Inc. boosted its stake in shares of Integer by 483.3% during the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 377 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Integer in the 4th quarter valued at about $1,375,000. Finally, Raymond James & Associates lifted its stake in Integer by 20.3% in the 4th quarter. Raymond James & Associates now owns 48,946 shares of the medical equipment provider’s stock valued at $4,850,000 after buying an additional 8,246 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. KeyCorp raised their price target on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. Benchmark raised their price target on shares of Integer from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. CL King assumed coverage on shares of Integer in a research note on Thursday, March 14th. They issued a “buy” rating and a $137.00 price target on the stock. Finally, Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and raised their price target for the company from $105.00 to $135.00 in a research note on Monday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and an average price target of $120.50.

Integer Trading Up 0.6 %

ITGR opened at $119.31 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71. The company’s 50 day simple moving average is $111.09 and its two-hundred day simple moving average is $97.94. Integer Holdings Co. has a 1-year low of $69.40 and a 1-year high of $121.53. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of 44.35, a price-to-earnings-growth ratio of 1.46 and a beta of 1.10.

Integer (NYSE:ITGR) last released its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.05. Integer had a net margin of 5.68% and a return on equity of 10.80%. The business had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. During the same period last year, the company posted $1.11 EPS. The business’s revenue was up 10.9% on a year-over-year basis. Analysts expect that Integer Holdings Co. will post 5.28 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.